scholarly journals Glaucoma Research Community and FDA Look to the Future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function

2011 ◽  
Vol 52 (11) ◽  
pp. 7842 ◽  
Author(s):  
Robert N. Weinreb ◽  
Paul L. Kaufman
Keyword(s):  
Clinical Trial ◽  
Structural Change ◽  
Visual Function ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Research Community ◽  
The Future

scholarly journals The Future of Clinical Trial Design in Oncology

2021 ◽  
Vol 11 (4) ◽  
pp. 822-837
Author(s):  
Anna Spreafico ◽  
Aaron R. Hansen ◽  
Albiruni R. Abdul Razak ◽  
Philippe L. Bedard ◽  
Lillian L. Siu
Keyword(s):  
Clinical Trial ◽  
Trial Design ◽  
Clinical Trial Design ◽  
The Future

The future of drug development: advancing clinical trial design

2009 ◽  
Vol 8 (12) ◽  
pp. 949-957 ◽  
Author(s):  
John Orloff ◽  
Frank Douglas ◽  
Jose Pinheiro ◽  
Susan Levinson ◽  
Michael Branson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Trial Design ◽  
Clinical Trial Design ◽  
The Future

scholarly journals Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0251585
Author(s):  
Pete Heinzelman ◽  
Philip A. Romero
Keyword(s):  
Clinical Trial ◽  
Genetic Variants ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Spike Protein ◽  
Single Nucleotide Variants ◽  
Single Nucleotide ◽  
Novel Variants ◽  
The Future ◽  
Fundamental Research

Understanding how human ACE2 genetic variants differ in their recognition by SARS-CoV-2 can facilitate the leveraging of ACE2 as an axis for treating and preventing COVID-19. In this work, we experimentally interrogate thousands of ACE2 mutants to identify over one hundred human single-nucleotide variants (SNVs) that are likely to have altered recognition by the virus, and make the complementary discovery that ACE2 residues distant from the spike interface influence the ACE2-spike interaction. These findings illuminate new links between ACE2 sequence and spike recognition, and could find substantial utility in further fundamental research that augments epidemiological analyses and clinical trial design in the contexts of both existing strains of SARS-CoV-2 and novel variants that may arise in the future.

scholarly journals The future is now: Model-based clinical trial design for Alzheimer's disease

2014 ◽  
Vol 97 (3) ◽  
pp. 210-214 ◽  
Author(s):  
K Romero ◽  
K Ito ◽  
JA Rogers ◽  
D Polhamus ◽  
R Qiu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Model Based ◽  
The Future

Integrating radiomics into clinical trial design

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Jessica J. Waninger ◽  
Michael D. Green ◽  
Catherine Cheze Le Rest ◽  
Benjamin Rosen ◽  
Issam El Naqa
Keyword(s):  
Clinical Trial ◽  
Trial Design ◽  
Clinical Trial Design

scholarly journals X-change symposium: status and future of modern radiation oncology—from technology to biology

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Stefanie Corradini ◽  
Maximilian Niyazi ◽  
Dirk Verellen ◽  
Vincenzo Valentini ◽  
Seán Walsh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radiation Oncology ◽  
Trial Design ◽  
Rapid Development ◽  
Clinical Trial Design ◽  
Current Status ◽  
Treatment Modalities ◽  
Special Treatment ◽  
Image Guided Radiotherapy

AbstractFuture radiation oncology encompasses a broad spectrum of topics ranging from modern clinical trial design to treatment and imaging technology and biology. In more detail, the application of hybrid MRI devices in modern image-guided radiotherapy; the emerging field of radiomics; the role of molecular imaging using positron emission tomography and its integration into clinical routine; radiation biology with its future perspectives, the role of molecular signatures in prognostic modelling; as well as special treatment modalities such as brachytherapy or proton beam therapy are areas of rapid development. More clinically, radiation oncology will certainly find an important role in the management of oligometastasis. The treatment spectrum will also be widened by the rational integration of modern systemic targeted or immune therapies into multimodal treatment strategies. All these developments will require a concise rethinking of clinical trial design. This article reviews the current status and the potential developments in the field of radiation oncology as discussed by a panel of European and international experts sharing their vision during the “X-Change” symposium, held in July 2019 in Munich (Germany).

Sign in / Sign up

Export Citation Format

Share Document